About

This document contains sensitive electronics. For best performance, do not bend, perforate or expose to extreme temperatures. This document also contains the following inactive ingredients: lactose monohydrate, povidone, microcrystalline cellulose, crospovidone, purified stearic acid, colloidal silicon dioxide, and purified water.

Most adverse events were mild or moderate and did not lead to discontinuation. The incidence of serious adverse events was 20% in the placebo group and 23% in this document's daily group. The percentage of patients who withdrew from treatment due to adverse events was approximately 17% in both this document's daily group and the placebo group. Overall, and according to body system, there was no difference between this document and a placebo, with adverse events of the digestive system being the most common reason for withdrawal.

In a 1-year, double-blind, multicenter study comparing exposure to this document once daily and exposure to this document once monthly in women with postmenopausal osteoporosis, the overall safety and tolerability profiles of the two oral dosing regimens were similar. The incidence of serious adverse events was 4.8% in the daily group and 7.1% in the once-monthly group. The percentage of patients who withdrew from treatment due to adverse events was approximately 8.9% in the daily group and 7.8% in the once-monthly group.